Skip to Main Content

BOSTON — Long seen as punching below its weight, the biopharma business in China is taking off. And here, nearly 7,000 miles away from Beijing, industry executives want in on the party.

That was the spirit animating a panel discussion put on Monday by the New England Healthcare Executive Network. By your correspondent’s informal count, the buzzword most repeated by speakers and audience members was “opportunity.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!